Merck Enhances Immuno-Oncology Portfolio with Acquisition of cCAM Biotherapeutics
Go back to Merck Enhances Immuno-Oncology Portfolio with Acquisition of cCAM Biotherapeutics| Merck & Co. (NYSE: MRK) | Delayed: 118.17 +2.69 (2.33%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $115.48 | 52 Week High | $65.46 | |||
| Open | $116.53 | 52 Week Low | $47.97 | |||
| Day High | $118.83 | P/E | 80.39 | |||
| Day Low | $116.53 | EPS | $1.47 | |||
| Volume | 1,412,754 | |||||
